30 November 2023FeaturesBiotechnologyMarisa Woutersen

Scientists and IP: Avoiding the pitfalls of publishing research

Publishing scientific findings after a patent application is filed can lead to more than a few potential pitfalls as a panel at LSPN Europe last week explored.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

European Commission commits €100bn for research and innovation

8 June 2018 The European Commission has proposed that the next long-term EU budget (2021-2027) includes €100 billion ($117.55 billion) for research and innovation, in what it calls the most ambitious such programme yet.

Americas

Novartis: opening the door to pharma research

31 May 2016 A firm advocate of ‘open innovation’, Novartis is setting aside rivalries and working on a number of projects to ensure patients get the best treatments as quickly as possible. LSIPR spoke to Graham Stuart of the company about some of the work.

More features

Trade secrets go global: How brand owners face a high-stakes battlefront

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Killing the golden goose of US drug innovation (Part I): Follow the money

Roche resolves cancer test dispute with Stanford affiliated startup

An update on patenting in Ukraine, Russia and Eurasia

The rise of pro-NPE and patent sentiment in the US

Why the Caribbean cannabis economy is ripe for IP protection

China filings push rise in patent applications in Ireland

Scientists and IP: Avoiding the pitfalls of publishing research

More on this story

Editor's picks

Editor's picks

More features